|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Chromatin immunoprecipitation identified ER genomic binding activity in estrogen-deprived cells and primary breast tumors treated with aromatase inhibitors.
|
22049316 |
2011 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
|
17119036 |
2006 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A similar magnitude suggestive association, although nonstatistically significant, was found between Val(80) polymorphism and estrogen receptor-negative status of the breast tumors.
|
19366906 |
2009 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.
|
15298966 |
2004 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
|
12114443 |
2002 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
|
18049890 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This clinically pertains, since aromatase inhibitors (AIs) are the most effective hormonal treatment of ERalpha-positive breast tumors.
|
19250199 |
2009 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
|
17975727 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
|
19064562 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
|
18245543 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, when combined with MSI/LOH in AR, ERβ and CYP19 genes, we were able to detect significant associations with the GSTP1 wild-type genotype in PR (progesterone receptor) negative breast cancers or the CYP17 wild-type genotype in ER (estrogen receptor) and PR-negative breast tumors.
|
28692125 |
2017 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
|
17562079 |
2007 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
|
18199708 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To block the growth of breast tumors, aromatase inhibitors (AIs) are employed to bind and inhibit aromatase in order to lower the amount of estrogen produced in the body.
|
30190660 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The aromatase enzyme complex, located primarily in the stromal cells of breast tumors, catalyzes estrogen biosynthesis and is fundamental to hormone-dependent growth of breast cancer.
|
12788892 |
2003 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> This study was undertaken to conduct a comprehensive investigation of the role of DNA damage repair (DDR) defects in poor outcome ER<sup>+</sup> disease.<b>Experimental Design:</b> Expression and mutational status of DDR genes in ER<sup>+</sup> breast tumors were correlated with proliferative response in neoadjuvant aromatase inhibitor therapy trials (discovery dataset), with outcomes in METABRIC, TCGA, and Loi datasets (validation datasets), and in patient-derived xenografts.
|
29793947 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Supporting data for an etiological role of aromatase in breast tumor biology are several-fold.
|
10731105 |
1999 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
|
25023195 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Biology of aromatase in the mammary gland.
|
14973387 |
2000 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
I.3, II, and I.7, is activated, leading to a marked increase in aromatase expression in breast tumors and breast adipose tissue adjacent to a breast tumor, and a consequent local overproduction of estrogen that promotes growth and progression of breast cancer.
|
18614276 |
2009 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors.
|
30513833 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The present study sought to provide more direct evidence of the predominant role for stromal cell aromatase in breast tumor tissue.
|
8989259 |
1997 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This hypothesis is sustained by the finding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue.
|
11973645 |
2002 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, RT-PCR analyses of RNA isolated from eight pairs of breast tumor and neighboring normal tissue specimens were performed to evaluate the exon I usage and the distribution of I.3A- and I.3B-containing aromatase RNA messages in breast tumor and neighboring normal tissues.
|
9010331 |
1996 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We determined the effects of the combination of RT and letrozole in the aromatase-expressing breast tumour cell line MCF-7CA, stably transfected with the CYP19 gene.
|
15642164 |
2005 |